Insparin Therapeutics is pioneering the development of a first-in-class therapy for Severe Insulin Resistance (SIR) and Severe Insulin Resistance Syndromes (SIRS), including several rare, orphan-designated conditions for which conventional diabetes treatments are ineffective.

Our lead therapeutic candidate, currently in preclinical development, is the first known compound capable of enhancing glucose uptake independent of insulin—a critical breakthrough in addressing the underlying pathology of SIRS.

Insparin’s mission is to bring transformative therapies to patients with few or no existing treatment options by advancing a targeted pipeline rooted in scientific innovation and unmet clinical need.